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A B S T R A C T
The endocannabinoid (eCB) system is one of the key players in immunoregulation, and reduced activity of the
eCB system has been linked with depressive-like behaviours in animal studies and depression in clinical samples.
There is a well-established link between immune activation and depression, such as following the administration
of the pro-inflammatory cytokine, interferon-α (IFN-α), used to treat hepatitis C viral (HCV) infection. However,
the role of peripheral endocannabinoids (eCBs), anandamide (AEA) and 2-arachidonoylglycerol (2-AG), fol-
lowing immunotherapy with IFN-α and in IFN-α -induced depression, have not been examined yet.
In this study, we investigated whether circulating AEA and 2-AG were modified by treatment with IFN-α and
whether they were involved in the development of IFN-α-induced depression. We also explored whether cir-
culating eCBs were associated with peripheral cytokines during and after IFN-α treatment. We measured serum
concentrations of AEA and 2-AG using High Performance Liquid Chromatography with Tandem Mass
Spectrometry, and serum concentrations of cytokines using Meso Scale Discovery electrochemiluminescence V-
PLEX assay, in 70 patients with HCV infection and 41 healthy subjects. We assessed HCV patients at baseline,
IFN-α-treatment weeks (TW) 4 and 24, end of treatment (END) and at six months follow-up (FU). We assessed
depression using M.I.N.I. International Neuropsychiatric Interview.
We found a different pattern of change in peripheral AEA and 2-AG during and after IFN-α treatment. Whilst
2-AG increased earlier in immunotherapy (TW4), remained elevated throughout treatment, and reduced at six
months follow-up (FU), AEA increased later in treatment (TW24) and remained elevated six months post-
treatment. We also found that baseline levels of AEA were lower in HCV patients compared with healthy con-
trols, whereas there were no differences in 2-AG levels. Interestingly, AEA, but not 2-AG, was significantly,
negatively correlated with interleukin (IL)-2 and IL-17a at six months follow-up. We did not find any difference
in both eCBs between patients with and without IFN-α-induced depression, at any time point.
Our findings suggest that AEA and 2-AG are involved in different stages of immunoregulation following IFN-α
treatment, where AEA might be involved in chronic inflammation. Lack of association between peripheral eCBs
and IFN-α-induced depression suggests that different biological mechanisms may underpin inflammation-in-
duced depression compared with classic “psychiatric” depression, or that any changes in the eCB system in
depression may not be captured by peripheral AEA and 2-AG.
1. Introduction
Considerable research suggests a bi-directional interaction between
the endocannabinoid (eCB) and immune systems, with the eCB system
being involved mainly in attenuation of inflammation through the
regulation of both, the innate and adaptive immune systems (Boorman
et al., 2016). However, most of the studies derive from preclinical
models and data in humans are lacking (Abidi et al., 2018; Fechtner
et al., 2019; Fitzgibbon et al., 2019). The eCB system is a homeostatic
signalling system with inhibitory properties identified following the
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discovery of the main psychoactive constituent of Cannabis Sativa L.,
Δ9-tetrahydrocannabinol (THC) (Gaoni & Mechoulam, 1964). This
system consists of three main components: 1) the endogenous lipid
transmitters called endocannabinoids (eCBs), the main ones being
anandamide (AEA) and 2-arachidonoylglycerol (2-AG) (Devane et al.,
1992; Mechoulam et al., 1995); 2) the target of these eCBs, the G-
protein-coupled receptors, cannabinoid receptor type 1 (CB1R) and
type 2 (CB2R) (Matsuda et al., 1990; Munro et al., 1993); and 3) en-
zymes involved in the synthesis of AEA and 2-AG, namely N-acyl
phosphatidylethanolamine phospholipase D (NAPE-PLD) and dia-
cylglycerol lipase (DAGL) (Bisogno et al., 2003; Okamoto et al., 2004)
respectively, and in the degradation of AEA and 2-AG, fatty acid amide
hydrolase (FAAH) and monoacylglycerol lipase (MAGL), respectively.
Evidence suggests an involvement of eCB signalling primarily in
decreasing inflammation (Crowe et al., 2014). For instance, CB2R ac-
tivation has been shown to attenuate inflammation in a range of in-
flammatory conditions including injury, inflammatory pain, hepatic
injury, periodontitis, multiple sclerosis, rheumatoid arthritis and in-
testinal inflammatory disorders (Abidi et al., 2018; Correa et al., 2011;
Fechtner et al., 2019; Pandey et al., 2009). Furthermore, levels of cir-
culating protein and mRNA encoding for interleukin- (IL)-1, IL-6 and
tumor necrosis factor (TNF)-α are reduced by the administration of
synthetic cannabinoids in preclinical models of multiple sclerosis and
periodontitis (Abidi et al., 2018; Croxford & Miller, 2003). In addition,
in an animal model of autoimmune hepatitis the administration of AEA
has been shown to diminish hepatic injury, and this is correlated with a
significant reduction in inflammatory cytokines, such as TNF-α, IL-1β,
IL-6, IL-9 and IL-17. The therapeutic effects of AEA are CB1R and CB2R
dependent, as blockade of the receptors independently inhibits the anti-
inflammatory effects (Hegde et al., 2008). Several types of immune cells
produce and regulate eCB activity, including macrophages, basophils,
lymphocytes and dendritic cells (Bisogno et al., 1997; Liu et al., 2003;
Maccarrone et al., 2001). For instance, rat macrophage and basophil
cells produce and degrade AEA (T Bisogno et al., 1997). In humans,
after one year of treatment with interferon- (IFN)-β in multiple
sclerosis, levels of AEA in natural killer (NK), T and B cells and ex-
pression of CB1R and CB2R in T and B cells, progressively decreased
(López et al., 2014).
The eCB system is also implicated in depression (Crowe et al., 2014;
Poleszak et al., 2018). Animal models suggest reduced functioning of
the system across receptor, enzyme and circulating eCBs activity (Fang
& Wang, 2018; Poleszak et al., 2018). Clinical investigations of eCB-
associated effects in depression are relatively sparse. Nonetheless
findings have, for the most part, verified the association between re-
duced eCB activity and depression. For example, Rimonabant, a CB1R
antagonist developed for use as an anti-obesity drug, was withdrawn
from the market due to serious adverse effects on mood that resulted in
onset of depression and suicidal ideation (Topol et al., 2010). Another
study reported that patients undergoing cardiac surgery who developed
depression six-months post operation, had significantly reduced plasma
levels of AEA and 2-AG during perioperative period (Hauer et al.,
2012). Furthermore, observational studies have shown reduced serum
levels of AEA and 2-AG in depressed women compared with healthy
controls, in one of which a reduction in serum 2-AG progressively de-
creased over the duration of the disorder (Hill et al., 2009, 2008). In-
terestingly, another study found that patients with depression who re-
ceived selective serotonin reuptake inhibitor (SSRI) treatment had
elevated plasma levels of 2-AG compared with those who were not on
antidepressant treatment, although this effect was not present for AEA
levels (Romero-Sanchiz et al., 2019). The notion of reduced eCB func-
tion in depression is particularly interesting in view of the putative anti-
inflammatory action of this system (discussed above), as there is a well-
established link between increased inflammatory state and depression.
In fact, several meta-analyses confirm the association between depres-
sion and increased inflammation, with depressed patients showing
elevated levels of IL-6, IL-1, TNF-α and C-reactive protein (CRP)
compared with healthy controls (Dowlati et al., 2010; Horn et al., 2018;
Howren et al., 2009; Perrin et al., 2019). Some studies have further
shown that increased peripheral inflammation might be associated with
different subtypes of depression, including treatment resistant depres-
sion and specific traits such as anhedonia or motor and cognitive
slowing (Haroon, Chen et al., 2018a; Haroon, Daguanno et al., 2018b;
Raison et al., 2013).
Prospective cohort studies have also reported that increased in-
flammatory state frequently leads to development of depression. For
example, in the most widely used model of inflammation-induced de-
pression, up to 45% of patients receiving pegylated- (peg)-IFN-α and
Ribavirin for hepatitis C virus (HCV) develop depression during the
course of treatment, alongside with an increase in levels of cytokines
and immune genes expression (Hepgul et al., 2016; Machado et al.,
2017; Perrin et al., 2019). However, no studies so far, explored the role
of eCBs in inflammation-induced depression.
In this study, we focused on the role of peripheral eCBs, AEA and 2-
AG, in patients with chronic HCV infection receiving peg-IFN-α treat-
ment, the aforementioned immune challenge and established model to
investigate inflammation-induced depression using a longitudinal de-
sign. We specifically measured changes in serum AEA and 2-AG before
and during IFN-α treatment (treatment weeks 4 and 24), at the end of
treatment (END), and six-months post-treatment, and investigated
whether these changes were associated with IFN-α induced depression.
We also measured peripheral cytokines to monitor the inflammatory
changes during and after IFN-α treatment, and their co-variance with
eCB levels. Finally, we looked at the relationship between the eCB and
immune systems six-months post-treatment with IFN-α, to measure any
potential recovery of eCB levels after the immune challenge was no
longer present. The comparison in eCB levels between patients with
HCV and healthy controls was also examined, since one previous study
found that plasma AEA and 2-AG were elevated in HCV patients com-
pared with the control group (Patsenker et al., 2015). To our knowl-
edge, this is the first study to use a prospective cohort design in order to
explore the role of peripheral eCBs, in both, patients with HCV re-
ceiving IFN-α treatment, and IFN-α induced depression.
2. Materials and methods
The study was approved by the South East London Research Ethics
Committee 3 (REC ref:10/H0808/30) and London Dulwich Research
Ethics Committee (REC ref: 12/LO/1368).
2.1. Participants
We recruited 70 patients with chronic HCV infection and compen-
sated liver disease, due to receive their treatment, from the Institute of
Liver Studies at King’s College Hospital in London, the Gastroenterology
Departments at St George’s, Queen Mary’s (Roehampton), St Thomas’
and Royal Free Hospitals in London. The age range of the HCV sample
was 18–68 years old. The treatment consisted of weekly, subcutaneous
injection of peg-IFN-α 2-b (1.5 mg/Kg) and daily Ribavirin (rib), ad-
ministered orally in doses ranging from 800 to 1400 mg. In addition to
IFN-α/rib, nine subjects (13%) were also prescribed a direct-acting
antiviral – ‘triple therapy’, adding boceprevir n = 1, telaprevir n = 4 or
simeprevir n = 2 (missing values n = 2), after treatment protocols
changed across the UK.
Exclusion criteria included presence of depression at baseline, use of
antidepressants at baseline, active substance abuse, pregnancy, any
autoimmune conditions, acute infections, or other than HCV causes for
liver disease, and language barrier (requiring interpreter). Clinical and
biological assessments were performed at treatment week (TW) 0
(baseline), TW4, TW24, and at the end of treatment (END) which
combined TW24, 36 or 48 depending on the duration of treatment
(TW24-81.43%, TW36-7.14% and TW48-11.43%). Then, patients were
followed up six-months after the end of treatment. A total of 28 patients
Z. Zajkowska, et al. Brain, Behavior, and Immunity 90 (2020) 248–258
249
(40%) developed depression at some point during IFN-α treatment,
whereas 42 patients (60%) did not develop depression. The attrition
rate at six months follow-up (FU) was 40%. There were no significant
differences between patients who dropped out compared with those
who did not, in age, gender, current tobacco and cannabis use, viral
load, fibroscan score or viral genotype (data not shown).
Healthy controls (N = 41), matched for age and gender, were re-
cruited from the community and from within King’s College London –
staff and students. The age range of healthy controls was 21–67 years
old. The inclusion criteria were as follows: no significant health con-
ditions, not taking any regular medication in the last 3 months prior to
the assessment (excluding contraception), not experienced a recent or
recurrent episodes of mental illness, no past or present substance abuse
or dependency. Healthy volunteers attended one visit at the Clinical
Research Facility at King’s College Hospital where all the clinical and
biological assessments were conducted. The sample was partially
overlapping with that in the publication by our colleagues (Hepgul
et al., 2016; Russell et al., 2019).
2.2. Clinical measures
We used the Mini International Neuropsychiatric Interview (MINI)
Major Depression section to assess the depression at baseline and the
development of IFN-α-induced depression in HCV patients during
treatment (TW4, 24 and END), and at six months follow-up. We used
the same measure to assess past and current depression in healthy vo-
lunteers (Sheehan et al., 1998). Other measures administered at base-
line included modified version of the Cannabis Experience Ques-
tionnaire to assess cannabis, tobacco and alcohol use (Barkus et al.,
2006), and Socio-Demographic Schedule (SDS) to record age, gender,
ethnicity, educational level, employment and relationship status
(Mallett et al., 2002). Demographic data are shown in Table 1.
2.3. HCV measures
We obtained the HCV RNA viral load from the patient medical re-
cords to assess the severity of the illness at baseline as well as treatment
response. The viral load was measured by the number of viral particles
per ml of blood, presented in millions (AmpiliPrep, Roche), where a
result of< 15 IU/ml equated to undetected. The viral load was mea-
sured at treatment week 4 to assess Rapid Virological Response (un-
detected virus at week 4 indicates likely treatment success), and six
months post-treatment to assess Sustained Virological Response which
determined treatment outcome. We also examined the degree of liver
damage by assessing liver stiffness reported in the Fibroscan result at
baseline. See Table 1 for full results on HCV measures.
2.4. Biological markers
In the HCV sample biological assessments were also conducted at
treatment weeks 0, 4, and 24, at the end of treatment, and at six months
follow-up. Due to the sample attrition, we were only able to collect data
from 42 patients at the six months follow-up. In the control group, we
performed all the biological assessments at the one-off visit. Blood
samples were collected using 6 mL BD vacutainer plastic tubes (silica
clot activator). Samples were left to clot for minimum 30 min at room
temperature and then centrifuged at 1850g for 10 min at room tem-
perature, following which, serum was removed and frozen at −80 °C.
We adjusted for the missing data by selecting only those samples which
had all the time points completed.
2.5. Endocannabinoids
AEA and 2-AG concentrations were analysed using High
Performance Liquid Chromatography (HPLC) with tandem mass spec-
trometry (MS/MS) detection. Samples were precipitated 1:4 with 80%
methanol, then vortexed and centrifuged at 16000×g for 5 min. The
internal standards D4-AEA and D5-2-AG (Cayman Chemicals, Ann
Arbor, MI) were added to the supernatant. Concentrations of AEA and
2-AG were determined by HPLC with tandem mass spectrometry (MS/
MS) detection, using D4-AEA and D5-2-AG as internal standards for the
analytes. 27 μL of each sample was injected onto the HPLC column by
an automated sample injector (SIL-10-20AC-HT, Shimadzu, Japan).
Chromatographic separation was performed on a reversed phase
column (100 × 2.1 mm, particle size 2.6 µm; Thermo), held at a
temperature of 45 °C. The mobile phases consisted of A: methanol:ul-
trapurified H2O (50:50) + 0.1% formic and B: methanol:ultrapurified
H2O (90:10) + 0.1% formic acid. Elution of the compounds proceeded
using a suitable linear gradient at a flow rate of 0.25 mL/min over
9 min. The MS analyses were performed using an API 5000 MS/MS
system consisting of an API 5000 MS/MS detector and a Turbo Ion
Spray interface (Applied Biosystems, the Netherlands). The acquisitions
on API 5000 were performed in positive ionization mode, with opti-
mized settings for the analytes (AEA: m/z 379 -> 269; 2-AG: m/z 348
-> 287). The instrument was operated in multiple-reaction-monitoring
(MRM) mode. Data were calibrated and quantified using the Analyst
data system (Applied Biosystems, version 1.4.2, the Netherlands).
Concentrations in experimental samples were calculated based on the
calibration curve in the corresponding matrix. The calibration curves
ranged from 0.025 nM to 20 nM for AEA and from 0.25 to 200 nM for 2-
AG (both from Cayman Chemicals, Ann Arbor, MI).
Table 1
Sample characteristics.
Measure at TW0* Patients n = 70 Controls n = 41 Test statistic  
Age (years) 
Mean SEM 
 
43.77 1.49 
 
42.61 1.89 
 
t (109) = .479, p=.63 
    
Gender/Males % 75.7% 68.3% X2 (1) = .722, p=.4 
    
Substance Use % 
Tobacco current 
Cannabis current 
 
 
34.4% 
16.4% 
 
19.5% 
14.6% 
 
X2 (1) = 2.705, p=.1 
X2 (1) = .061, p=.81 
    
HCV Genotype % 
1 
2 
3 
4 
 
19.7% 
15.2% 
59.1% 
6.1% 
 
N/A 
 
N/A 
    
HCV viral load (million) 
Mean SEM  
 
2.74 0.39 
 
N/A 
 
N/A 
    
Fibroscan Score (KPa) 
Mean SEM 
 
9.39 1.01 
 
N/A 
 
N/A 
*Treatment week (TW).
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2.6. Cytokines
Meso Scale Discovery (MSD) electrochemiluminescence V-PLEX
assay was used to measure cytokines including IL-2, IL-6, IL-4, IL-8, IL-
10, IL-13, TNF-α, IL-7 and IL-17a (pg/mL). Serum samples were diluted
2-fold and measured in duplicate. The cytokines concentration was
determined with the electrochemiluminescent labels whilst the plate is
inserted into the MSD instrument (MESO QUICKPLEX SQ 120). All
samples were assayed in duplicate. High and low controls were used to
assess variance between plates. The inter-assay coefficient of variations
was<10%. The results were analysed using MSD DISCOVERY WOR-
KBENCH analysis software.
2.7. Data analysis
All data were analysed with IBM SPSS statistical software version
22. For the graphic representation of the data, unless otherwise stated,
the mean score is presented with error bars representing the standard
error of the mean (SEM). The significance value for all tests was set at
α = 0.05. To examine differences between two groups in continuous
variables, independent samples t-tests were used, where data was
normally distributed. Where equal variance could not be assumed, as
assessed by the Levene’s test (p < 0.05), the results reported are those
where the degrees of freedom have been adjusted using the Welch-
Satterthwaite method. Where data was not normally distributed, a post-
hoc Mann-Whitney U test of difference was used. To measure changes
in eCB levels during and after treatment, and differences in eCB levels
between patients with and without IFN-α induced depression, we used
two-way mixed ANOVA model followed by the Bonferroni correction
for multiple comparisons. To measure changes in cytokine levels during
and after treatment in the HCV sample, we used one-way repeated
measures ANOVA model followed by the Bonferroni correction for
multiple comparisons. Where data were not normally distributed,
logarithmic transformations of the data were used. Where skewness was
addressed successfully, log transformed analysis was reported, and
post-hoc analyses were performed using parametric tests. Where the
attempts to transform the data proved unsuccessful, analysis was per-
formed on the raw data, and post-hoc analyses were performed using
appropriate non-parametric test. Where the assumption of sphericity
was violated (p < 0.05) as indicated by Mauchly’s test, results re-
ported are those with the Greenhouse-Geisser [G-G] correction to the
degrees of freedom applied. Associations between two continuous
variables were explored using Pearson’s product moment correlations
(Pearson’s r; r), where data for both variables was linear and normally
distributed. Where data was not linear, log transformations were per-
formed and analyses run on transformed data. Where data was not
normally distributed Spearman’s rank correlation co-efficient
(Spearman’s Rho; rs) was used.
Fig. 1. Panel a) AEA levels in HCV patients during IFN-α treatment presented at baseline and at treatment weeks 4 and 24, and in healthy controls at baseline; panel
b) 2-AG levels in HCV patients during IFN-α treatment presented at baseline and at treatment weeks 4 and 24, and in healthy controls at baseline.
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3. Results
3.1. IFN-α treatment increases serum AEA and 2-AG in patients with HCV
We first analysed the peripheral AEA and 2-AG levels before IFN-α
treatment, in patients with HCV and healthy controls. We found that
HCV patients showed significantly lower baseline serum AEA levels
compared with healthy controls (U = 1989.5, z = 3.39, p = .001). No
significant difference was found for baseline serum 2-AG between pa-
tients and controls (t (109) = 0.001, p = .99) (see Fig. 1).
Then, we looked at changes in AEA and 2-AG levels in patients with
HCV during IFN-α treatment. Although both AEA and 2-AG increased
significantly during treatment, the pattern of change was different for
each eCB (AEA: F (2, 136) = 73.66, p < .001, partial n2 = 0.52; 2-AG:
F (1.27, 87.35) = 10.32, p = .001, partial n2 = 0.13). Whilst 2-AG
increased significantly at TW4 (p = .001) and remained elevated until
TW24, AEA increased later during treatment, at TW24 (p < .001) (see
Fig. 1).
Finally, we looked at changes in AEA and 2-AG levels between end
of treatment and six-months post-treatment. These analyses were con-
ducted separately due to the sample being smaller (n = 42 vs. n = 70)
as follow-up serum was not available for everybody. In addition, we
also compared follow-up values with those of healthy controls, as by
then most (n = 33 out of n = 42) HCV patients had responded to the
antiviral therapy. In these analyses, AEA remained elevated at follow
up, even in the absence of IFN-α (F (2, 78) = 34.19, partial n2 = 0.47,
p < .001) and remained elevated even when compared with healthy
controls (t (81) = 2.740, p = .008). In contrast, 2-AG levels reduced at
follow-up compared with end of treatment (F (1.34, 52.4) = 15.61,
partial n2 = 0.29, p < .001) and were not significantly different from
controls (U = 710.500, z = -1.379, p = .17) (see Fig. 2).
3.2. Serum AEA and 2-AG in IFN-α induced depression
Firstly, we explored the difference in peripheral AEA and 2-AG le-
vels at baseline, between patients who went on to develop depression
and patients who did not develop depression during IFN-α treatment.
We performed this analysis to understand whether eCBs can be used as
potential predictors of IFN-α induced depression. We did not find any
significant difference in AEA and 2-AG levels at baseline between pa-
tients with and without IFN-α induced depression (AEA: t
(68) = −0.035, p = .97; 2-AG: t (68) = 1.605, p = .11).
Subsequently, we analysed the changes in AEA and 2-AG levels
during IFN-α treatment and six-months post-treatment in patients with
and without IFN-α induced depression. We found no significant dif-
ferences nor group × time interactions in AEA and 2-AG levels between
Fig. 2. Panel a) AEA levels after IFN-α treatment in HCV patients presented at baseline, end of treatment (END) and at six months follow-up (FU), and in healthy
controls at baseline; panel b) 2-AG levels after IFN-α treatment in HCV patients presented at baseline, end of treatment (END) and at six months follow-up (FU), and
in healthy controls at baseline.
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depressed and non-depressed patients during (AEA main group effect: F
(1, 68) = 1.169, p = 0.28, partial n2 = 0.17; AEA group × time: F (2,
136) = 0.211, p = 0.81, partial n2 = 0.003; 2-AG main group effect: F
(1, 69) = 0.017, p = .89, partial n2 = 0.006; 2-AG group × time: F
(1.266, 87.350) = 0.347, p = .61, partial n2 = 0.005) and after IFN-a
treatment (AEA main group effect: F(1, 39) = 0.000, p = 0.99, partial
n2 = 0.91; AEA group × time: F (2, 78) = 0.993, p = 0.38, partial
n2 = 0.25; 2-AG main group effect: F(1, 39) = 0.955, p = .33, partial
n2 = 0.24; 2-AG group × time: F (1.344, 52.403) = 1.718, p = 0.19,
partial n2 = 0.042). These results are presented in Figs. 3 and 4. The
data indicate that the increase in AEA and 2-AG we observed is in-
dependent of depression development.
3.3. Association between peripheral inflammation and endocannabinoids
during and after IFN-a treatment in HCV patients
We wanted to understand the relationship between eCBs and cyto-
kines during the immune activation following IFN-α treatment. To do
that, we measured cytokines in the HCV patients during treatment and
six months post-treatment (these cytokines data on a larger, over-
lapping sample, have already been presented by our group in Russell
et al., 2019). To limit the number of multiple comparisons, we selected
the cytokines that significantly changed during this period and corre-
lated them with eCB levels measured at the same time point. During
IFN-a treatment, HCV patients showed significant increase in serum IL-
2, IL-6, IL-17a and TNF-a (all at weeks 4 and 24), and decrease in serum
IL-4 (at week 4). At six months post-treatment, HCV patients showed a
significant decrease in serum IL-2, IL-6, IL-10, IL-17a and TNF-α com-
pared with end of treatment, and all cytokines at this time point were
no longer different from their baseline levels, except for IL-10, which
was lower than its baseline levels (see Table 2). Given that all cytokines
affected by IFN-a treatment decreased at six months follow-up, we also
explored if they were associated with the significantly elevated levels of
AEA at six months follow-up.
We found no significant correlations between all selected cytokines
and both eCBs (AEA and 2-AG) during IFN-a treatment. However, we
found that six months post-treatment, AEA was moderately and nega-
tively correlated with IL-2 (r = -0.44, p = .01) and IL-17a (rs = -0.39,
p = .02) levels, and there were trends for negative, weak correlations
with IL-6 (rs = -0.33, p = .06) and IL-10 (r = -0.31, p = .08) (see
Table 3).
Lastly, we wanted to see whether any associations found were also
present before IFN-a treatment. We found negative, weak correlation
between AEA and IL-2 at baseline (rs = −0.339, p = .03) and no
significant correlation between baseline AEA and IL-17a (rs = −0.01,
p = .96) (see Table 3).
Fig. 3. Panel a) AEA levels in HCV patients with and without onset of depression during IFN-α treatment presented at baseline and at treatment weeks 4 and 24;
panel b) 2-AG levels in HCV patients with and without onset of depression during IFN-α treatment presented at baseline and at treatment weeks 4 and 24.
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4. Discussion
We found that peripheral AEA and 2-AG were affected by HCV in-
fection and IFN-α treatment. However, they were not associated with
IFN-α induced depression. To our knowledge, this is the first study to
use a prospective cohort design in order to explore the role of periph-
eral eCBs, in both, patients with HCV receiving IFN-α treatment, and
IFN-α induced depression.
We demonstrated an increase in AEA and 2-AG levels during and
after IFN-α treatment, albeit with a different pattern of change. We
found that AEA increased at a later stage during treatment (TW24) and
remained elevated even after treatment ended (six months follow-up).
2-AG on the other hand, increased earlier (TW4) and remained elevated
during treatment, however, it returned to baseline levels six months
post-treatment. This suggests that AEA and 2-AG might be involved in
different stages of the immune response following IFN-α injection,
where AEA continues playing part in more chronic inflammation.
Previous research has shown that AEA participates in reducing in-
flammation while 2-AG can both, reduce and facilitate the in-
flammatory response (Chiurchiù et al., 2016; Gasperi et al., 2014;
Hegde et al., 2008). For example, AEA reduced hepatic injury and the
production of pro-inflammatory cytokines in autoimmune hepatitis
(Hegde et al., 2008), and it was shown to suppress T cell proliferation
and reduce cytokine production in several other studies (Cencioni et al.,
2010; Chiurchiù et al., 2016; Schwarz et al., 1994). In contrast, 2-AG,
has been shown to promote leukocyte recruitment by increasing the
expression of adhesion molecules and TNF-α levels, which help leuko-
cyte migration to the injury site (Gasperi et al., 2014). Furthermore, 2-
AG has been found to increase levels of nitric oxide, a component of the
inflammatory response (Chang et al., 2001). In another study, the in-
flammatory stimulation of human platelets and mouse macrophages
with platelet activating factor (PAF) resulted in the immediate release
Fig. 4. Panel a) AEA levels in HCV patients with and without onset of depression after IFN-α treatment presented at baseline, end of treatment (END) and at six
months follow-up (FU); panel b) 2-AG levels in HCV patients with and without onset of depression after IFN-α treatment presented at baseline, end of treatment
(END) and at six months follow-up (FU).
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of 2-AG but not AEA (Berdyshev, 2000). Differential regulation of AEA
and 2-AG was also reported in response to lipopolysaccharide (LPS) in
mouse macrophages, where only AEA levels increased following LPS
stimulation, contributing to LPS-induced hypotension (Liu et al., 2003).
Similarly, in another study only AEA levels were altered following LPS
stimulation in the mice amygdala (Doenni et al., 2016). Although we
might hypothesize, that the difference in the timing of increase between
the two eCBs which we observe in our study might be due to different
functions of AEA and 2-AG in the immune regulation, we cannot make
strong statements due to the observational nature of our study.
In our sample, we did not find any difference in peripheral AEA and
2-AG in relation to IFN-α induced depression, before, during and after
IFN-α treatment. Based on the previous literature, showing lower levels
of eCBs in depression, we hypothesized that patients who developed
depression at some stage during IFN-α treatment would have had lower
baseline eCBs, making them more susceptible to depression, and that
lower eCB levels would continue throughout treatment and beyond, in
patients who develop depression (M. N. Hill et al., 2009). However,
previous studies reporting eCB deficiency in depression did not in-
vestigate inflammation-induced depression, and it is possible that this
“subtype” of depression is not associated with reduced eCBs (Doenni
et al., 2016; Liu et al., 2003; Patsenker et al., 2015). As previous studies
have shown, increased inflammation can lead to elevated eCB levels
and elevated inflammation has been reported in a subgroup of de-
pressed patients who are not responsive to antidepressant treatment
(Doenni et al., 2016; Haroon, Daguanno et al., 2018b; Raison et al.,
2013). This suggests that eCB levels might vary depending on the
“subtype” of depression, albeit presence or absence of increased in-
flammation. The lack of association between eCB signalling and de-
pressive-like behaviours in the presence of increased inflammation has
been also reported in a preclinical model, where inhibition of the FAAH
enzyme showed attenuation of neuroinflammation but no changes in
depressive-like behaviour (Flannery et al., 2018). It is impossible to
establish whether these two eCBs truly do not play any role in IFN-α
induced depression (differently from “psychiatric” major depression),
or simply we are not using the right biomarkers. In this regard, for
example, we have shown, in a sub-sample of patients from this study,
that patients who developed IFN-α-induced depression showed in-
creased whole blood mRNA expression of immune markers which was
not mirrored by an increase in circulating cytokines (Hepgul et al.,
2016). This could be true for eCB markers as well, given the complex
nature of this system (Hillard, 2017; Patsenker et al., 2015). Lastly, we
are yet to understand whether peripheral eCB signalling mirrors eCB
activity in the brain. We know from the current research that patients
with psychiatric conditions, e.g., depression tend to have lower levels of
circulating eCBs compared with healthy individuals, which suggests
that there is a link between central nervous system (CNS) and periph-
eral eCBs (N. Hill et al., 2008; Hillard, 2017). Evidence from the recent
study looking at eCBs in CNS showed increase in AEA levels in the
cerebrospinal fluid of depressed patients following electroconvulsive
therapy, which suggests that such form of antidepressant treatment
resulted in elevated eCB signalling in the CNS. However, the same study
reported no correlation between depressive symptoms decrease and
AEA increase, and AEA levels were positively associated with depres-
sive symptoms pre-treatment (Kranaster et al., 2017). We also know
that peripheral eCBs can be transported across the blood–brain barrier
(BBB) through endothelial cell membranes of brain microvessels
(Boorman et al., 2016). However, we do not have sufficient evidence to
say that circulating eCBs might reflect endocannabinoid levels in the
brain (Hillard, 2017). To understand such correlation, more studies are
needed looking at both, CNS and peripheral levels of eCBs.
Finally, we did not find any association between cytokines and
endocannabinoids during IFN-a treatment. However, we found that six
months post-treatment, AEA levels were negatively associated with IL-2
and IL-17a, and, at a trend-level significance, with IL-6 and IL-10.
Interestingly, we also found negative association between AEA and IL-2Ta
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at baseline. One possible explanation could be that IFN-α treatment,
because of its strong immune effects, may have masked such associa-
tions. We know from the previous studies that activation of the immune
system can increase eCBs, which in turn are capable of reducing the
inflammatory response (Abidi et al., 2018; Patsenker et al., 2015). For
example, AEA was shown to inhibit IL-2 production in the peripheral
blood mononuclear cells of the HCV patients (Patsenker et al., 2015). In
another study, AEA supressed proliferation of human peripheral T cells,
stimulated with CD3, CD19 and CD28 antibodies via CB2 receptors. It
was suggested that AEA acted through the inhibition of DNA synthesis
(Cencioni et al., 2010; Schwarz et al., 1994). Furthermore, AEA in-
hibited IL-2 production, a key growth factor in T cells proliferation and
supressed the release of pro-inflammatory cytokines, TNF-α, IFN-γ and
IL-17, which are part of the TH1 response (Cencioni et al., 2010). In-
deed, in our study we observe that both eCBs increase during IFN-a
treatment but only AEA remains elevated six months post-treatment,
whereas 2-AG returns to baseline levels. This would suggest a bi-di-
rectional association between inflammatory processes and circulating
AEA which occur six months post IFN-α treatment.
In our sample we found that HCV patients showed significantly
lower baseline serum AEA levels compared with healthy controls,
however there was no difference in serum 2-AG levels across the two
groups. This is inconsistent with previous research showing elevated
plasma levels of AEA and 2-AG in HCV patients compared with the
control group (Patsenker et al., 2015). Strong evidence from the re-
search on stress, suggests that chronic stress exposure attenuates eCB
activity and reduces circulating eCBs (Yi et al., 2016). Living with the
devastating, chronic condition such as HCV infection means that these
patients are more likely to be exposed to higher levels of stress for a
long period of time due to the nature of the disease itself. However,
measures of stress were outside the scope for this study. Of note is that
the majority of patients in our sample had HCV genotype 3, which
could have also affected baseline immune responses, and subsequently
eCB levels.
One of the limitations of this study is the sample size which was
smaller than originally intended. Recent changes in NHS England af-
fected the number of patients receiving IFN-α treatment and a large
proportion of patients were treated through clinical trials. Additionally,
early discontinuation of treatment and baseline comorbidities reduced
the sample size, and the retention rate was 60% at six months follow-
up. Therefore, we may have been underpowered to detect associations
between eCBs and depression. Also, we did not collect data that were
likely to influence circulating eCBs, such as exercise and food intake.
Controlling for these factors would be the recommended next step in
the future research.
Although IFN-α treatment is no longer a standard treatment for
HCV, the results from this study provide a valuable insight into the role
of peripheral eCBs in response to the immune challenge, suggesting
their involvement in the immunomodulation. Future studies are needed
to confirm whether these findings extend beyond HCV sample and IFN-
α treatment. Although interpreted with caution, together with the
findings from previous studies, our study provides further evidence that
targeting eCB signalling may be of interest as an anti-inflammatory
treatment in the future.
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